Ligand Pharmaceuticals Inc (LGND)

103.56
0.97 0.95
NASDAQ : Health Care
Prev Close 102.59
Open 102.40
Day Low/High 100.25 / 103.68
52 Wk Low/High 71.63 / 138.94
Volume 251.15K
Avg Volume 390.40K
Exchange NASDAQ
Shares Outstanding 20.90M
Market Cap 2.21B
P/E Ratio 67.43
Div & Yield N.A. (N.A)

Latest News

SHAREHOLDER ALERT: Goldberg Law PC Announces Securities Class Action Lawsuit Against Ligand Pharmaceuticals Incorporated And Encourages Investors With Losses To Contact The Firm

SHAREHOLDER ALERT: Goldberg Law PC Announces Securities Class Action Lawsuit Against Ligand Pharmaceuticals Incorporated And Encourages Investors With Losses To Contact The Firm

Goldberg Law PC, a national shareholder rights litigation firm, announces the filing of a class action lawsuit against Ligand Pharmaceuticals Incorporated ("Ligand" or the "Company") (Nasdaq: LGND).

IMPORTANT INVESTOR ALERT: Lundin Law PC Announces Securities Class Action Lawsuit Against Ligand Pharmaceuticals Incorporated And Encourages Investors With Losses To Contact The Firm

IMPORTANT INVESTOR ALERT: Lundin Law PC Announces Securities Class Action Lawsuit Against Ligand Pharmaceuticals Incorporated And Encourages Investors With Losses To Contact The Firm

Lundin Law PC, a shareholder rights firm, announces the filing of a class action lawsuit against Ligand Pharmaceuticals Incorporated ("Ligand" or the "Company") (Nasdaq: LGND) concerning possible violations of federal...

EQUITY ALERT: Rosen Law Firm Files Securities Class Action Lawsuit Against Ligand Pharmaceuticals Incorporated - LGND

EQUITY ALERT: Rosen Law Firm Files Securities Class Action Lawsuit Against Ligand Pharmaceuticals Incorporated - LGND

Rosen Law Firm, a global investor rights law firm, announces that it has filed a class action lawsuit on behalf of purchasers of Ligand Pharmaceuticals Incorporated securities (NASDAQ:LGND) from November 9, 2015 through...

EQUITY ALERT: Rosen Law Firm Announces Investigation Of Securities Claims Against Ligand Pharmaceuticals Incorporated

EQUITY ALERT: Rosen Law Firm Announces Investigation Of Securities Claims Against Ligand Pharmaceuticals Incorporated

Rosen Law Firm, a global investor rights law firm, announces it is investigating potential securities claims on behalf of shareholders of Ligand Pharmaceuticals Incorporated (NASDAQ: LGND) resulting from allegations...

SHAREHOLDER ALERT: Goldberg Law PC Announces An Investigation Of Ligand Pharmaceuticals Incorporated And Advises Investors With Losses To Contact The Firm

SHAREHOLDER ALERT: Goldberg Law PC Announces An Investigation Of Ligand Pharmaceuticals Incorporated And Advises Investors With Losses To Contact The Firm

Goldberg Law PC, a national shareholder rights litigation firm, announces that it is investigating Ligand Pharmaceuticals Incorporated ("Ligand" or the "Company") (Nasdaq: LGND) concerning possible violations of...

IMPORTANT SHAREHOLDER ALERT: Lundin Law PC Announces An Investigation Of Ligand Pharmaceuticals Incorporated And Advises Investors With Losses To Contact The Firm

IMPORTANT SHAREHOLDER ALERT: Lundin Law PC Announces An Investigation Of Ligand Pharmaceuticals Incorporated And Advises Investors With Losses To Contact The Firm

Lundin Law PC, a shareholder rights firm, announces that it is investigating claims against Ligand Pharmaceuticals Incorporated ("Ligand" or the "Company") (Nasdaq: LGND) concerning possible violations of federal...

Ligand Reports Third Quarter 2016 Financial Results

Ligand Reports Third Quarter 2016 Financial Results

Ligand Pharmaceuticals Incorporated (NASDAQ: LGND) today reported financial results for the three and nine months ended September 30, 2016, and provided an operating forecast and program updates.

Ligand Partner Melinta Therapeutics Submits Baxdela New Drug Application For Hospital-Treated Skin Infections

Ligand Partner Melinta Therapeutics Submits Baxdela New Drug Application For Hospital-Treated Skin Infections

Ligand Pharmaceuticals Incorporated (NASDAQ: LGND) partner Melinta Therapeutics, a privately held company developing novel antibiotics to treat serious bacterial infections, announced today that it has submitted New Drug...

Ligand Announces Third Quarter 2016 Earnings Release Date And Participation In The Stephens Fall Investment Conference

Ligand Announces Third Quarter 2016 Earnings Release Date And Participation In The Stephens Fall Investment Conference

Ligand Pharmaceuticals Incorporated (NASDAQ: LGND) announced today plans to report third quarter 2016 financial results on November 3, 2016.

Mylan: 1 of 2 Beaten-Down Biopharmas to Buy

Mylan: 1 of 2 Beaten-Down Biopharmas to Buy

Both it and Ligand Pharmaceuticals look significantly undervalued relative to their prospects.

Ratings Changes Today

TheStreet Quant Ratings provides fair and objective information to help you make educated investing decisions. We rate over 4,300 stocks daily and provide 5-page PDF reports for each stock. These ratings can change daily and today's changes are reflected in the email below. If you are looking to check-up on the stocks you currently own or are looking for new ideas, you can find our full database of password-protected ratings reports in our proprietary ratings screener: http://www.thestreet.com/k/qr/flat/stock-screener.html Upgrades: MENT Downgrades: ELS, FRBK, LGND, MOG.B, SXL, THC Initiations: None Read on to get TheStreet Quant Ratings' detailed report:

Ligand Partner Lundbeck Receives FDA Approval Of Carnexiv™ (carbamazepine) Injection As Intravenous Short-Term Replacement Therapy For Certain Seizure Types

Ligand Partner Lundbeck Receives FDA Approval Of Carnexiv™ (carbamazepine) Injection As Intravenous Short-Term Replacement Therapy For Certain Seizure Types

Ligand Pharmaceuticals Incorporated (NASDAQ: LGND) partner Lundbeck announced today that the U.

Ligand Licenses Four Programs To Seelos Therapeutics

Ligand Licenses Four Programs To Seelos Therapeutics

Ligand Pharmaceuticals Incorporated (NASDAQ: LGND) announces the licensing of rights to four programs to Seelos Therapeutics, Inc.

Ligand Enters OmniAb® License Agreement With TeneoBio, Inc.

Ligand Enters OmniAb® License Agreement With TeneoBio, Inc.

Ligand Pharmaceuticals Incorporated (NASDAQ: LGND) announces it has entered into a worldwide license agreement with Menlo Park, CA-based TeneoBio, Inc.

Ligand Initiates Phase 2 Trial With LGD-6972 In Type 2 Diabetes

Ligand Initiates Phase 2 Trial With LGD-6972 In Type 2 Diabetes

Ligand Pharmaceuticals Incorporated (Nasdaq: LGND) announces the initiation of a Phase 2 clinical trial with the Company's glucagon receptor antagonist LGD-6972 for the treatment of type 2 diabetes mellitus (T2DM).

Retrophin (With Help From Martin Shkreli) Advances Drug for Rare Kidney Disease

Retrophin (With Help From Martin Shkreli) Advances Drug for Rare Kidney Disease

Retrophin announced positive results from a study in which patients with a rare kidney disease responded to treatment with its experimental drug sparsentan.

Analysts' Actions -- ConocoPhillips, Discover, DineEquity, Maxim and More

Analysts' Actions -- ConocoPhillips, Discover, DineEquity, Maxim and More

Here are Wednesday's top research calls, including upgrades for ConocoPhillips and DineEquity, and downgrades for Discover and Maxim.